MedTrace Logo

Intrathecal Therapy With Monoclonal Antibodies in Progressive Multiple Sclerosis

NCT01719159 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2016-11-22

No results posted yet for this study

Summary

This is a is a small scale open phase two interventional study to assess long-term stabilising effects of on neurological symptoms by regular intrathecal administered monoclonal antibodies in progressive multiple sclerosis.

Conditions

Interventions

DRUG

Rituximab

25 mg rituximab is injected intrathecally via an Ommaya reservoir once a week for 3 weeks. Patients are then followed for one year.

Sponsors & Collaborators

  • Västerbotten County Council, Sweden

    collaborator OTHER_GOV

  • Anders Svenningsson

    lead OTHER

Principal Investigators

  • Anders Svenningsson, MD, PhD · Umea university

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-11-30
Primary Completion
2016-06-30
Completion
2016-06-30

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01719159 on ClinicalTrials.gov